1
|
Huhtaniemi R, Oksala R, Knuuttila M, Mehmood A, Aho E, Laajala TD, Nicorici D, Aittokallio T, Laiho A, Elo L, Ohlsson C, Kallio P, Mäkelä S, Mustonen MV, Sipilä P, Poutanen M. Adrenals Contribute to Growth of Castration-Resistant VCaP Prostate Cancer Xenografts. THE AMERICAN JOURNAL OF PATHOLOGY 2018; 188:2890-2901. [DOI: 10.1016/j.ajpath.2018.07.029] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/12/2018] [Revised: 07/24/2018] [Accepted: 07/30/2018] [Indexed: 01/01/2023]
|
2
|
Chiarella P, Vulcano M, Bruzzo J, Vermeulen M, Vanzulli S, Maglioco A, Camerano G, Palacios V, Fernández G, Brando RF, Isturiz MA, Dran GI, Bustuoabad OD, Ruggiero RA. Anti-inflammatory pretreatment enables an efficient dendritic cell-based immunotherapy against established tumors. Cancer Immunol Immunother 2008; 57:701-18. [PMID: 17962945 PMCID: PMC11030084 DOI: 10.1007/s00262-007-0410-4] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2007] [Accepted: 09/19/2007] [Indexed: 01/20/2023]
Abstract
Although animals can be immunized against the growth of some tumor implants, most of the attempts to use immunotherapy to cause the regression of animal and human tumors once they have become established have been disappointing even when strongly immunogenic tumors were used as target. In this paper, we demonstrate that the failure to achieve an efficient immunological treatment against an established strongly immunogenic murine fibrosarcoma was paralleled with the emergence of a state of immunological unresponsiveness (immunological eclipse) against tumor antigens observed when the tumor surpassed the critical size of 500 mm(3). In turn, the onset of the immunological eclipse was coincidental with the onset of a systemic inflammatory condition characterized by a high number of circulating and splenic polymorphonucleated neutrophils (PMN) displaying activation and Gr1(+)Mac1(+) phenotype and an increasing serum concentration of the pro-inflammatory cytokines TNF-alpha, IL-1beta and IL-6 cytokines and C-reactive protein (CRP) and serum A amyloid (SAA) phase acute proteins. Treatment of tumor-bearing mice with a single low dose (0.75 mg/kg) of the synthetic corticoid dexamethasone (DX) significantly reduced all the systemic inflammatory parameters and simultaneously reversed the immunological eclipse, as evidenced by the restoration of specific T-cell-dependent concomitant immunity, ability of spleen cells to transfer anti-tumor activity and recovery of T-cell signal transduction molecules. Two other anti-inflammatory treatments by using indomethacin or dimeric TNF-alpha receptor, also partially reversed the immunological eclipse although the effect was not as striking as that observed with DX. The reversion of the immunological eclipse was not enough on its own to inhibit the primary growing tumor. However, when we used the two-step strategy of inoculating DX to reverse the eclipse and then dendritic cells loaded with tumor antigens (DC) as an immunization booster, a significant inhibition of the growth of both established tumors and remnant tumor cells after excision of large established tumors was observed, despite the fact that the vaccination alone (DC) had no effect or even enhanced tumor growth in certain circumstances. The two-step strategy of tumor immunotherapy that we present is based on the rationale that it is necessary to eliminate or ameliorate the immunological eclipse as a precondition to allow an otherwise ineffective anti-tumor immunological therapy to have a chance to be successful.
Collapse
Affiliation(s)
- Paula Chiarella
- División Medicina Experimental (ILEX CONICET), Academia Nacional de Medicina de Buenos Aires, Pacheco de Melo 3081, 1425 Buenos Aires, Argentina
| | - Marisa Vulcano
- División Inmunología, Academia Nacional de Medicina de Buenos Aires, Pacheco de Melo 3081, 1425 Buenos Aires, Argentina
- Present Address: Research Laboratory in Immunology and Inflammation, Istituto Clinico Humanitas, Rozzano, Milan, Italy
| | - Juan Bruzzo
- División Medicina Experimental (ILEX CONICET), Academia Nacional de Medicina de Buenos Aires, Pacheco de Melo 3081, 1425 Buenos Aires, Argentina
| | - Mónica Vermeulen
- División Inmunología Oncológica, Instituto de Investigaciones Hematológicas (IIHEMA), Academia Nacional de Medicina de Buenos Aires, Pacheco de Melo 3081, 1425 Buenos Aires, Argentina
| | - Silvia Vanzulli
- Instituto de Estudios Oncológicos (IEO), Academia Nacional de Medicina de Buenos Aires, Pacheco de Melo 3081, 1425 Buenos Aires, Argentina
| | - Andrea Maglioco
- División Medicina Experimental (ILEX CONICET), Academia Nacional de Medicina de Buenos Aires, Pacheco de Melo 3081, 1425 Buenos Aires, Argentina
| | - Gabriela Camerano
- División Medicina Experimental (ILEX CONICET), Academia Nacional de Medicina de Buenos Aires, Pacheco de Melo 3081, 1425 Buenos Aires, Argentina
| | - Víctor Palacios
- Centro de Estudio y Tratamiento Oncológico (CETRO), Academia Nacional de Medicina de Buenos Aires, Pacheco de Melo 3081, 1425 Buenos Aires, Argentina
| | - Gabriela Fernández
- División Inmunología, Academia Nacional de Medicina de Buenos Aires, Pacheco de Melo 3081, 1425 Buenos Aires, Argentina
| | - Romina Fernández Brando
- División Inmunología, Academia Nacional de Medicina de Buenos Aires, Pacheco de Melo 3081, 1425 Buenos Aires, Argentina
| | - Martín A. Isturiz
- División Medicina Experimental (ILEX CONICET), Academia Nacional de Medicina de Buenos Aires, Pacheco de Melo 3081, 1425 Buenos Aires, Argentina
- División Inmunología, Academia Nacional de Medicina de Buenos Aires, Pacheco de Melo 3081, 1425 Buenos Aires, Argentina
| | - Graciela I. Dran
- División Medicina Experimental (ILEX CONICET), Academia Nacional de Medicina de Buenos Aires, Pacheco de Melo 3081, 1425 Buenos Aires, Argentina
| | - Oscar D. Bustuoabad
- División Medicina Experimental (ILEX CONICET), Academia Nacional de Medicina de Buenos Aires, Pacheco de Melo 3081, 1425 Buenos Aires, Argentina
| | - Raúl A. Ruggiero
- División Medicina Experimental (ILEX CONICET), Academia Nacional de Medicina de Buenos Aires, Pacheco de Melo 3081, 1425 Buenos Aires, Argentina
| |
Collapse
|
3
|
Demetrikopoulos MK, Weiss JM, Goldfarb RH. Environmental Factors and Disease: Stress and Cancer. Compr Physiol 2001. [DOI: 10.1002/cphy.cp070422] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
4
|
Gillissen G. "Inverse" effects of cortisone in experimental infection of mice. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 1992; 319:137-43. [PMID: 1414589 DOI: 10.1007/978-1-4615-3434-1_15] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Hydrocortisone (HC) ameliorated the course of experimental infection with E. coli given intraperitoneally. In experiments with Staphylococcus aureus and treatment with endotoxin on the day of infection, HC had also a beneficial effect, however only when LPS was injected intraperitoneally and bacteria intravenously. With the footpad swelling reaction as a model for cellular immunity it could be shown that HC alone reduced the reactivity by 75 per cent. Under endotoxin treatment, however, HC induced further inhibition when LPS was given intraperitoneally the day of sensitization but changing to a stimulatory effect when LPS was given two days later. In case of intravenous application of LPS, HC had no effect.
Collapse
Affiliation(s)
- G Gillissen
- Department of medical Microbiology, Faculty of Medicine, University of Aachen, Federal Republic of Germany
| |
Collapse
|